Testing two medications together for neuroendocrine tumors that stopped responding to other drugs

This trial is testing a combination of two medications—Cabozantinib and Temozolomide—given together to treat neuroendocrine tumors (rare cancers that develop in hormone-producing cells). The trial focuses on people whose tumors have stopped responding to earlier treatments like everolimus, sunitinib, or radiation therapy. Researchers believe that combining these two medications may help slow or stop tumor growth by attacking cancer cells in different ways.

People with neuroendocrine tumors often run out of treatment options after their first therapy stops working. This medication combination targets two important pathways scientists believe help these tumors grow, offering hope for patients who need a new treatment option.